Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C.
Hepatitis C virus (HCV) genotype 1 infections are significantly more difficult to eradicate with PEG-IFN/ribavirin therapy, compared to HCV genotype 2. The aim of this work is to investigate the difference of immunological impairments underlying this phenomenon. Pre-treatment NKG2D expression on per...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4428701?pdf=render |
| _version_ | 1818119923623264256 |
|---|---|
| author | Po-sung Chu Hirotoshi Ebinuma Nobuhiro Nakamoto Kazuo Sugiyama Shingo Usui Yuko Wakayama Nobuhito Taniki Akihiro Yamaguchi Shunsuke Shiba Yoshiyuki Yamagishi Takaji Wakita Toshifumi Hibi Hidetsugu Saito Takanori Kanai |
| author_facet | Po-sung Chu Hirotoshi Ebinuma Nobuhiro Nakamoto Kazuo Sugiyama Shingo Usui Yuko Wakayama Nobuhito Taniki Akihiro Yamaguchi Shunsuke Shiba Yoshiyuki Yamagishi Takaji Wakita Toshifumi Hibi Hidetsugu Saito Takanori Kanai |
| author_sort | Po-sung Chu |
| collection | DOAJ |
| description | Hepatitis C virus (HCV) genotype 1 infections are significantly more difficult to eradicate with PEG-IFN/ribavirin therapy, compared to HCV genotype 2. The aim of this work is to investigate the difference of immunological impairments underlying this phenomenon. Pre-treatment NKG2D expression on peripheral CD56+CD3+ lymphocytes and CD56+CD3- NK cells from cases of chronic hepatitis C were analyzed and assessed by treatment effect. Two strains of HCV were used to co-incubate with immune cells in vitro. NKG2D expression on peripheral CD56+CD3+ lymphocytes, but not NK cells, was significantly impaired in genotype 1 infection, compared to genotype 2. When peripheral blood mononuclear cells from healthy donors were co-incubated with TNS2J1, a genotype 1b/2a chimera strain, or with JFH1, a genotype 2a strain, genotype-specific decrease of NKG2D on CD56+CD3+ lymphocytes, but not NK cells, was observed. Pre-treatment NKG2D expression on peripheral CD56+CD3+ lymphocytes significantly correlated with reduction in serum HCV RNA levels from week 0 to week 4, and predicted treatment response. Ex vivo stimulation of peripheral CD56+CD3+ lymphocytes showed NKG2D expression-correlated IFN-γ production. In conclusion, Decreased NKG2D expression on CD56+CD3+ lymphocytes in chronic HCV genotype 1 infection predicts inferior treatment response to PEG-IFN/ribavirin therapy compared to genotype 2. |
| first_indexed | 2024-12-11T05:17:55Z |
| format | Article |
| id | doaj.art-88d5174904f94edd93b05ba46834d2eb |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T05:17:55Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-88d5174904f94edd93b05ba46834d2eb2022-12-22T01:19:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01105e012566410.1371/journal.pone.0125664Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C.Po-sung ChuHirotoshi EbinumaNobuhiro NakamotoKazuo SugiyamaShingo UsuiYuko WakayamaNobuhito TanikiAkihiro YamaguchiShunsuke ShibaYoshiyuki YamagishiTakaji WakitaToshifumi HibiHidetsugu SaitoTakanori KanaiHepatitis C virus (HCV) genotype 1 infections are significantly more difficult to eradicate with PEG-IFN/ribavirin therapy, compared to HCV genotype 2. The aim of this work is to investigate the difference of immunological impairments underlying this phenomenon. Pre-treatment NKG2D expression on peripheral CD56+CD3+ lymphocytes and CD56+CD3- NK cells from cases of chronic hepatitis C were analyzed and assessed by treatment effect. Two strains of HCV were used to co-incubate with immune cells in vitro. NKG2D expression on peripheral CD56+CD3+ lymphocytes, but not NK cells, was significantly impaired in genotype 1 infection, compared to genotype 2. When peripheral blood mononuclear cells from healthy donors were co-incubated with TNS2J1, a genotype 1b/2a chimera strain, or with JFH1, a genotype 2a strain, genotype-specific decrease of NKG2D on CD56+CD3+ lymphocytes, but not NK cells, was observed. Pre-treatment NKG2D expression on peripheral CD56+CD3+ lymphocytes significantly correlated with reduction in serum HCV RNA levels from week 0 to week 4, and predicted treatment response. Ex vivo stimulation of peripheral CD56+CD3+ lymphocytes showed NKG2D expression-correlated IFN-γ production. In conclusion, Decreased NKG2D expression on CD56+CD3+ lymphocytes in chronic HCV genotype 1 infection predicts inferior treatment response to PEG-IFN/ribavirin therapy compared to genotype 2.http://europepmc.org/articles/PMC4428701?pdf=render |
| spellingShingle | Po-sung Chu Hirotoshi Ebinuma Nobuhiro Nakamoto Kazuo Sugiyama Shingo Usui Yuko Wakayama Nobuhito Taniki Akihiro Yamaguchi Shunsuke Shiba Yoshiyuki Yamagishi Takaji Wakita Toshifumi Hibi Hidetsugu Saito Takanori Kanai Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. PLoS ONE |
| title | Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. |
| title_full | Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. |
| title_fullStr | Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. |
| title_full_unstemmed | Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. |
| title_short | Genotype-Associated Differential NKG2D Expression on CD56+CD3+ Lymphocytes Predicts Response to Pegylated-Interferon/Ribavirin Therapy in Chronic Hepatitis C. |
| title_sort | genotype associated differential nkg2d expression on cd56 cd3 lymphocytes predicts response to pegylated interferon ribavirin therapy in chronic hepatitis c |
| url | http://europepmc.org/articles/PMC4428701?pdf=render |
| work_keys_str_mv | AT posungchu genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT hirotoshiebinuma genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT nobuhironakamoto genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT kazuosugiyama genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT shingousui genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT yukowakayama genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT nobuhitotaniki genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT akihiroyamaguchi genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT shunsukeshiba genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT yoshiyukiyamagishi genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT takajiwakita genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT toshifumihibi genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT hidetsugusaito genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc AT takanorikanai genotypeassociateddifferentialnkg2dexpressiononcd56cd3lymphocytespredictsresponsetopegylatedinterferonribavirintherapyinchronichepatitisc |